{
  "docId": "019de074-ad31-7288-aa0c-b4a964d6a9af",
  "docSlug": "31aafddb38d645745d1c40d83b8ae135",
  "documentTitle": "ATAI | Investor Presentation Deck | 30 slides",
  "authorId": "atai",
  "authorName": "atai",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 30,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a checkmark matrix to highlight the competitive advantage of the drug candidate.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ad31-7288-aa0c-b4a964d6a9af/20",
  "deckHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af",
  "deckJsonHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af.json",
  "deckAnchorHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.2,
        "x": 0.03,
        "y": 0.22
      },
      "kind": "paragraph",
      "text": "There is an unmet need in GAD for therapies with rapid onset, high efficacy, and minimal side effects. SSRI/SNRI's are current standard of care for GAD but require 4-6 weeks for onset of effect and have several disadvantages.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0e9441d-9765-4a13-bdcc-4f3af8aa24db",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.25,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Note: GABA = Gamma aminobutyric acid, SERT = serotonin transporter, NET = serotonin transporter; MoA = Mechanism of Action; 5HT1a = serotonin 1A receptor; VDCC = voltage dependent calcium channel; TSPO = mitochondrial translocator protein. Source: Publicly available information, including company websites and clinicaltrials.gov, GlobalData, Evaluate Pharma (both as of 2022). 1. DeMartini et al., “Generalized Anxiety Disorder” (2019)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "878ecd9e-9e77-4f56-8a05-ed65d9234e53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.7,
        "x": 0.25,
        "y": 0.2
      },
      "kind": "table",
      "text": "Comparison table of GAD therapeutic options including Benzoxazine, SSRI, SNRI, Benzodiazepines, TCA, Azapirones, and Gabapentinoid across safety and efficacy criteria.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e32edfaa-0671-4578-8739-f32447b67c60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.25,
        "y": 0.05
      },
      "kind": "title",
      "text": "GRX-917 is developed to address unmet need in Generalized Anxiety Disorder (GAD) with rapid onset and favorable safety",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79672153-e783-4393-8fa3-3970d3148671",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "6968f22f-3c9f-404d-9f1e-653ee827b5f9",
      "evidence": "The slide uses a matrix to compare the subject drug against existing market alternatives.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 9,
      "beatId": "ac5e080c-b74d-4115-a83a-25ce54f0c50b",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 9-24 present traction data for various programs",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8a640552-7d64-4f46-af4c-8041a39da251",
      "evidence": "The deck presents a clear and compelling vision for ATAI's mission and solution",
      "position": 1,
      "objective": "Present a compelling vision for ATAI's mission and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}